A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

Explore 2025's groundbreaking scientific discoveries: the MoM-z14 galaxy, personalised CRISPR therapy, regenerative medicine, ...

Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to keep in mind that Vertex retains 60% of Casgevy profit while CRISPR ...

Satyen K. Bordoloi My first memory of cancer is the younger brother of a classmate. Blood cancer, we whispered between ...

Across sectors, tech majors worldwide blurred the line between experimental and practical, pushing the world into a new phase ...

Cambodia border conflict, and the AI race are among the 10 prominent international events in 2025 as selected by the Vietnam News Agency.

Now, Musunuru and colleagues are preparing a master clinical protocol to study a CRISPR therapy that's mostly the same as the one they used to treat baby KJ, except they plan to swap out the gene ...

Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, ...

Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam ...

On the roads, motor-vehicle deaths — which spiked during the pandemic — have now fallen for several years in a row: the ...

Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...